The following represents disclosure information provided by authors of this abstract. The ASCO-NCI-EORTC Annual Meeting on Molecular Markers in Cancer Planning Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Uptake of BRAF and ALK mutation screening versus HER2 overexpression testing.
Savanna Steele
No relevant relationships to disclose
Savanna D. Steele
Disclosure not yet available
Austin J. Combest
No relevant relationships to disclose
Marie-Edith Anne Bonneterre
No relevant relationships to disclose
Joseph Walt Adair
No relevant relationships to disclose
Eric Barefield
No relevant relationships to disclose
Dirk J. Reitsma
No relevant relationships to disclose